SCHEMBL2174354

SCHEMBL2174354

CC(C)(C)OC(=O)NCc1nc(C(=O)NCCc2cccc(Cl)c2)cs1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 3/20 0.52
HDAC1 Q13547 3/20 0.52
HDAC6 Q9UBN7 3/20 0.52
IGF1R P08069 1/20 0.51
KDM4E B2RXH2 1/20 0.48
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
HTT P42858 3/20 0.47
HIF1A Q16665 2/20 0.46
MAPT P10636 3/20 0.46
TRPV1 Q8NER1 1/20 0.44
MEN1 O00255 1/20 0.44
GAA P10253 1/20 0.44
KMT2A Q03164 1/20 0.44
ALDH1A1 P00352 1/20 0.43
THRB P10828 1/20 0.43
IDO1 P14902 1/20 0.43
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5670028 0.85 IGF1R (0.56) IGF1RNPC1RAB9ASMN1; SMN2HTT
SCHEMBL2171406 0.82 SMN1; SMN2 (0.57) IGF1RNPC1RAB9ASMN1; SMN2HTT
SCHEMBL2172312 0.81 KDM4E (0.48) KDM4ENPC1RAB9ASMN1; SMN2HTT
Hydrochloric Acid SCHEMBL2173104 0.81 SMN1; SMN2 (0.56) IGF1RNPC1RAB9ASMN1; SMN2HTT
SCHEMBL5668870 0.80 IGF1R (0.51) IGF1RNPC1RAB9ASMN1; SMN2HTT
SCHEMBL2173461 0.80 TRPV1 (0.58) IGF1RNPC1RAB9ASMN1; SMN2HTT
SCHEMBL25834083 0.80 KDM4E (0.63) KDM4ENPC1RAB9ASMN1; SMN2HTT
SCHEMBL10126403 0.79 IGF1R (0.52) IGF1RNPC1RAB9ASMN1; SMN2HTT
SCHEMBL18765041 0.79 SMN1; SMN2 (0.58) HDAC3HDAC1HDAC6SMN1; SMN2HTT
SCHEMBL2172958 0.79 CNR1 (0.54) IGF1RNPC1RAB9ASMN1; SMN2HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973061-B2 Anaplastic lymphoma kinase modulators and methods of use EXELIXIS, INC. (US) 2011-07-05 US disclosed
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2009-07-23 US disclosed
EP-1730128-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2006-12-13 EP disclosed
WO-2005097765-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE ALK, BCL3, MCL1 HDAC3 691/4885HDAC1 1046/4885HDAC6 1698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.